Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-08-27 Sale | 2024-08-29 6:36 pm | Spero Therapeutics Inc. | SPRO | Shukla Sath CEO & President | 2,757 | $1.35 | $3,722 | 1,140,809 (Direct) | View |
| 2024-08-02 Sale | 2024-08-06 7:56 pm | Spero Therapeutics Inc. | SPRO | Shukla Sath CEO and President | 32,441 | $1.3146 | $42,646 | 1,143,566 (Direct) | View |
| 2024-02-02 Sale | 2024-02-05 8:40 pm | Spero Therapeutics Inc. | SPRO | Shukla Sath CEO and President | 75,994 | $1.4175 | $107,719 | 1,176,007 (Direct) | View |
| 2023-08-28 Sale | 2023-08-30 4:20 pm | Spero Therapeutics Inc. | SPRO | Shukla Sath CEO and President | 6,017 | $1.2877 | $7,748 | 572,500 (Direct) | View |
| 2023-02-02 Sale | 2023-02-03 7:41 pm | Spero Therapeutics Inc. | SPRO | Shukla Sath Chief Financial Officer | 9,504 | $1.8279 | $17,372 | 312,517 (Direct) | View |
| 2022-08-29 Sale | 2022-08-30 5:00 pm | Spero Therapeutics Inc. | SPRO | Shukla Sath Chief Financial Officer | 6,017 | $0.8938 | $5,378 | 56,064 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-02-01 Option Award | 2024-02-05 8:40 pm | N/A N/A | Spero Therapeutics Inc. | SPRO | Shukla Sath CEO and President | 679,501 | $0 | 1,176,007 (Direct) | View |
| 2023-08-01 Option Award | 2023-08-03 4:10 pm | N/A N/A | Spero Therapeutics Inc. | SPRO | Shukla Sath CEO and President | 266,000 | $0 | 578,517 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-03 7:41 pm | N/A N/A | Spero Therapeutics Inc. | SPRO | Shukla Sath Chief Financial Officer | 265,957 | $0 | 312,517 (Direct) | View |
| 2022-02-01 Option Award | 2022-02-03 4:19 pm | N/A 2032-02-01 | Spero Therapeutics Inc. | SPRO | Shukla Sath Chief Financial Officer | 91,204 | $0 | 115,271 (Direct) | View |
| 2021-08-26 Option Award | 2021-08-30 4:15 pm | N/A N/A | Spero Therapeutics Inc. | SPRO | Shukla Sath Chief Financial Officer | 24,067 | $0 | 24,067 (Direct) | View |
| 2021-01-04 Option Award | 2021-01-05 4:20 pm | N/A 2031-01-04 | Spero Therapeutics Inc. | SPRO | Shukla Sath Chief Financial Officer | 75,000 | $0 | 75,000 (Direct) | View |
| 2020-01-29 Option Award | 2020-01-31 4:52 pm | N/A 2030-01-29 | ZIOPHARM ONCOLOGY INC | ZIOP | Shukla Sath EVP, Chief Financial Officer | 204,400 | $0 | 204,400 (Direct) | View |